Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: DrugBank:APRD00627 (MAP)
 15,705 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effect of short-term (10 days) Medroxyprogesterone acetate (MPA) administration on side reactions of combination chemotherapy with ADR, VDS and CDDP for primary lung cancer was studied by comparisons of MPA administration group (20 cases) with non administration group (30 cases). 1) Frequency of vomiting, duration of nausea and body weight loss were significantly improved in MPA administration Group (p less than 0.01). 2) Leukocyte and neutrophil counts in MPA administration group especially 7-10 days after of chemotherapy were maintained higher than these of non administration group (p less than 0.05). 3) Major side effects including thromboembolism in MPA administration group had not been observed. These results indicated that short-term MPA administration was relatively safe and effective in combination chemotherapy including CDDP.
 ...
PMID:[Effect of short-term administration of medroxyprogesterone acetate on side reactions of combination chemotherapy with ADR, VDS and CDDP in primary lung cancer]. 182 10

In this informal initial study, four female patients with intractable chronic abdominal pain, daily nausea, intermittent vomiting, and altered stool habits due to "functional" disease were investigated. A gonadotropin-releasing hormone (GnRH) analog agonist, leuprolide acetate (Lupron) [D-leu6, Desgly-NH2(10), Proethylamide9], was administered once daily (0.5 mg subcutaneously) for three months. At the end of the three-month period, three subjects were symptom-free and the fourth experienced only mild and intermittent pain. The leuprolide regimen was continued for an additional three months, and estrogen (0.625 mg orally) and calcium (1000 mg orally) were given daily to prevent osteoporosis. The patients remained symptom-free. A challenge with progesterone then induced recurrence of mild symptoms in each subject. Withdrawing leuprolide induced the baseline symptoms in all patients within three to five days. This regimen has now been continued for up to 15 months, and all four patients have remained generally symptom-free. Progesterone has also been given every three months to induce menses. A fifth patient, with Roux-en-Y syndrome, has also been treated with leuprolide. She is symptom-free after six months and has gained weight. In this initial observation period in patients with severe functional (neuromuscular) bowel disease, the GnRH analog agonist leuprolide controlled pain, nausea, and vomiting.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Debilitating "functional" bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog. 249 61

The present paper concerns two multicenter studies on adjuvant therapy with medroxyprogesterone acetate (MAP) for operable N+ breast cancer. The patients entered the study between April 1979 and March 1986. One hundred and fifty-one premenopausal patients were randomly assigned to receive either polychemotherapy (CMF) or CMF + MAP. One hundred and thirty-eight postmenopausal patients were randomized to receive either MAP h.d. or no treatment. CMF was administered according the following schedule: cyclophosphamide mg 100/ms p.o. 1-4 days; methotrexate mg 40/ms i.v. and fluorouracil mg 600/ms i.v. 1st and 8th days. The cycle was repeated six times every 28 days. MAP was administered at 1000 mg X 2/daily p.o. for 30 days and afterwards 500 mg X 2/daily for 5 months. In the premenopausal study after a median follow-up of 36 months no difference was observed in the incidence of recurrence, site of recurrence, actuarial 5-year disease-free survival (DFS) or overall survival (OS). In the postmenopausal study a statistically significant lower number of recurrences was observed in MAP-treatment patients after a median follow-up of 37 months. The effect of MAP was limited to patients with less than or equal to 3 metastatic axillary lymph nodes. In addition, there are suggestions that only patients with ER+ tumors draw some advantage from the treatment. On the other hand, no difference exists in the OS. The treatments were substantially well tolerated. The MAP + CMF regimen induces lower vomiting compared to the CMF alone. The most frequent MAP side-effects were vaginal spotting (16%) and tremors (12%). We conclude that MAP h.d., like tamoxifen and aminoglutethimide, can improve the DFS of operable N+ breast cancer in postmenopausal patients.
 ...
PMID:Adjuvant therapy for operable breast cancer with medroxyprogesterone acetate alone in postmenopausal patients or in combination with CMF in premenopausal patients. 296 62

The term "pregnancy interception" covers all fertility control methods that interfere with implantation of the fertilized egg, either by inhibiting its transport or implantation or by eliminating the already implanted blastocyst. A few researchers beginning in 1960 used high doses of estrogen in the immediate postovulatory period to prevent implantation. It was discovered that administration had to occur soon after coitus to be effective. Estrogens were administered orally for 5 days beginning in the 72 hours following unprotected intercourse in the ovulatory phase. Secondary effects were common: vomiting in 40% of cases, menometrorrhagia in 30%, and almost constant breast discomfort. About 10% of pregnancies in case of failure of the method were ectopic. The mechanism of action is still not understood. A combined treatment of 50 mcg ethinyl estradiol and a 19-norsteroid progestin has been used since 1975. It must be administered in the 48 hours following coitus and repeated 12 hours later. The duration of treatment and quantity of hormones are significantly reduced, but the secondary effects are similar to those of estrogens used alone, and the failure rate is 2%. Some progestins can also be used alone. IUD insertion up to 7 days after the unprotected intercourse has a contragestive effect, but the risk of infection is considerable and 3% of patients develop endometritis. The risk of secondary sterility discourages use of the method, especially in nulliparas. The prostaglandins E and F are effective in early pregnancy termination, but their side effects considerably limit their use. The average duration of bleeding is acceptable, but prostaglandins cause very painful uterine contractions in 30-40% of cases. Gastrointestinal secondary effects often require termination of treatment. The recent synthesis and use of the antiprogesterone compound RU-486 offers real promise for a widely usable contragestive method. Progesterone is indispensable for the continuation of pregnancy, and inhibiting its action on the endometrium interrupts pregnancy. An antiprogesterone acts by competing directly with progesterone at the target cells. The antiprogesterone RU-486 also has dose-dependent luteolytic and antigonadotropic effects whose mechanisms are not completely understood. Clinical trials have proven the innocuity of RU-486, and its efficacy of about 90% will undoubtedly be improved. Interruption of early pregnancy is a major indication for RU-486. The duration of the pregnancy appears to be the determining factor in the percentage of success, but most researchers have had failure rates of 15% even in pregnancies of less than 5 weeks. Possible heavy bleeding or failure in case of ectopic pregnancy indicate the need for medical surveillance. A different route of administration and combination with a small dose of prostaglandin would undoubtedly raise the success rate. RU-486 may have more promise as a post-coital agent, and may potentially be the basis for development of a once-a-month pill.
 ...
PMID:[Contragestion]. 365 95

A possible relation between parenteral Depo-Provera and the subsequent development of medullary infarction in a heavy smoker is reported. The patient, a 40-year old Chinese woman had smoked 30 cigarettes daily for many years. She received injections of 150 mg Depo-Provera in April and July 1979. 2 days after the 2nd injection she was admitted to the hospital for vomiting and vertigo of 2 days duration. Clinical examination showed a 12th nerve palsy with the tongue deviated to the right but no other neurological abnormalities. She was treated symptomatically with intravenous fluids and stemetil and improved. On the 5th day her vertigo and vomiting progressed and she developed more lower brain stem signs. The same day she had a grand mal fit and went into a coma. She died on the 7th hospital day. A partial autopsy limited to the skull revealed minimal atherosclerosis of the vertebral artery but no thrombosis or occlusion. Cut sections after perfusion revealed an area of softening associated with some hemorrhage involving the whole length of the right half of the medulla oblongata dorsal to the olivary nucleus. Histological examination revealed an infarct undergoing liquefaction necrosis. The possibility of a causative relationship is suggested by the development of tinnitis about 12 hours after injection of Depo-Provera.
 ...
PMID:Medullary infarction--was it depo-provera? 645 93

A 42-year-old woman was administered a cleansing enema to treat chronic constipation. Immediately after the procedure she developed intense pain in the abdominal region, nausea, vomiting, and rectal bleeding. The patient, who was in good general health, had been on contraceptive administration of Depo-Provera (150 mg each month) for 1 year. Radiological investigation, endoscopy and histopathological examinations revealed acute ischemic colitis. A left hemicolectomy was performed with colorectal anastomosis through laparotomy; the postoperative period was good and the patient was discharged in good health. The majority of cases of ischemic colitis occur in persons of advanced age, because of arteriosclerosis. In young female patients it is necessary to systematically investigate contraceptive use as a possible iatrogenic cause; surgery may be indicated in some cases.
 ...
PMID:Ischemic colitis attributable to a cleansing enema. 725 Sep

This is the report of results from a phase 2 trial of high-dose progestin therapy for treatment of ovarian cancer. 19 women received 1000 mg of Depo Provera (medroxyprogesterone acetate) weekly by intramuscular injection for at least 8 weeks and longer if there was no evidence of tumor progression. None of the women in the study was responding any longer to surgery, radiation therapy, or conventional cytotoxic chemotherapy. Response was measured as: 1) regression if there was at least a 50% decrease in the area of measurable lesion; or 2) disease progression as at least a 25% increase over the original measurements or the appearance of new lesions. Based on these criteria, there were no responses in the 19 women. Only 1 patient remained stable (3 months). Median survival time was 2 months with 75% of the patients dying within 4 months. 1 patient suffered severe vomiting and another experienced bleeding; there was no other toxicity. It is concluded that progestin therapy does not have a beneficial effect and its use in ovarian cancer patients should be limited to those with endometrioid histology.
 ...
PMID:Progestin therapy for advanced ovarian cancer: a phase II Eastern Cooperative Oncology Group trial. 727 26

Abortion was induced in 20 women who were less than 49 days pregnant with a vaginal suppository containing 3.0 mg (15S)-15-methyl-(PGF2alpha) prostaglandin F2 alpha methyl ester. Peripheral serum levels of (15S)-15-methylPGF2alpha free acid, betahCG, and progesterone were measured before, during the 10 hours after treatment, and over the next 14 days. 18 of the subjects had a complete follow-up; 10 were aborted (53%), 3 had incomplete abortions, and 5 were failures. There was a correlation between serum levels of F2alpha (15S)-15-methyl-PGF2alpha free acid, and the incidence of success. Progesterone was significantly reduced in all 3 groups of subjects and therefore could not be utilized to judge the success of the procedure. A small but insignificant reduction of betahCG occurred in all subjects regardless of outcome during the 18-hour observation period. Since minor side effects of diarrhea and vomiting occurred in less than 1/2 of the aborted and only a few of the nonaborted sujects, a larger amount of drug might improve the success rate.
 ...
PMID:Termination of early gestation with a single vaginal suppository of (15S)-15-methyl-prostaglandin F2alpha methyl ester. 744 79

In order to determine the usual dose in the first line therapy and a high dose in the second or third line therapy, a dose finding study of a novel antiestrogen NK 622 (toremifene citrate) was performed in patients (pts) with advanced or recurrent breast cancer. NK 622 was orally administered daily once for more than 8 weeks. In pts without previous drug therapy or in pts with cancer relapse after adjuvant therapy, the response rates [(CR + PR)/total] were 24.1% (7/29), 13.8% (4/29), 20.0% (1/5) and 40.0% (2/5) at doses of 40, 60, 120 and 240 mg/day, respectively. A 40 mg/day dose showed an objective response only in postmenopausal pts with estrogen receptor (ER) positive or unknown cancer. At a dose of 60 mg/day, some of the responding cases were premenopausal pts or pts with ER(-) cancer. In pts with cancer relapse during adjuvant therapy or in those with previous therapy and/or radiation, response rates were 25.0% (2/8), 0% (0/4), 13.5% (5/37) and 10.3% (4/39) at doses of 40, 60, 120 and 240 mg/day, respectively. Response was more frequent in pts with ER (+) cancer than with ER (-) cancer. The response rates in pts with previous therapy including tamoxifen (TAM) except medroxyprogesterone (MPA) were 14.3% (4/28) at a 120 mg/day dose and 6.1% (2/33) at a 240 mg/day dose. In pts with previous therapy including TAM, MPA and other antitumor agents, the rate was 18.2% (2/11) at a 120 mg/day dose. Side effects such as elevation of GOT, GPT and serum Ca level, decrease of hemoglobin, anorexia, nausea/vomiting, fatigue, dizziness and hot flush were observed. These side effects were moderate in grade and reversible. Dose dependency of side effects was not clearly observed in grade and incidence. From these results, NK 622 is expected to be a safe drug with efficacy in first line therapy at a dose of 40 mg/day and in second or third line therapy at a dose of 120 mg/day.
 ...
PMID:[Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study]. 842 89

A multi-center randomized comparison study of CAF + TAM therapy (Arm A) and CAF + MPA therapy (Arm B) in advanced or recurrent breast cancer was conducted at 37 institutions in Kyushu. Out of 119 registered cases, 114 were eligible and 76 were evaluable. The response rate was 42% (15/36) in Arm A and 58% (23/40) in Arm B. In the comparison of side effects, nausea/vomiting and anorexia were significantly less and moon face and body weight gain were significantly more in Arm B. Leucocytopenia was significantly inhibited in Arm B compared with Arm A, which indicated the myeloprotective effect of MPA. These results indicated that CAF + MPA therapy (Arm B) may be more advantageous than CAF + TAM therapy (Arm A) in advanced or recurrent breast cancer.
 ...
PMID:[Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer]. 860 18


1 2 Next >>